Soleno Therapeutics (NASDAQ:SLNO) released its quarterly earnings data on Wednesday. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.13), Bloomberg Earnings reports.
NASDAQ SLNO traded up $0.07 on Friday, reaching $2.00. The company had a trading volume of 69,731 shares, compared to its average volume of 68,924. The company has a 50 day moving average of $2.56. The company has a market capitalization of $63.24 million, a PE ratio of -3.08 and a beta of 2.29. Soleno Therapeutics has a 52 week low of $1.11 and a 52 week high of $5.07.
A number of equities research analysts recently commented on SLNO shares. Zacks Investment Research downgraded Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Laidlaw started coverage on Soleno Therapeutics in a report on Monday, July 8th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, ValuEngine downgraded Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, June 24th.
About Soleno Therapeutics
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017.
Further Reading: How does a reverse stock split work?
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.